👤 Riping Wu

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
1732
Articles
1210
Name variants
Also published as: Jiake Wu, Ming-Jiuan Wu, Siying Wu, Yijian Wu, Fong-Li Wu, Chih-Chung Wu, Jin'en Wu, D P Wu, Zhongwei Wu, Zixiang Wu, Haiping Wu, Geyan Wu, Qi-Zhu Wu, Jianjin Wu, Shwu-Yuan Wu, Su Wu, Xiaodi Wu, Changxin Wu, Kuen-Phon Wu, Guofeng Wu, Zhiping Wu, Xiaojun Wu, Qibing Wu, Cheng-Hsin Wu, Junhua Wu, Xiaoting Wu, Wenze Wu, Hong Wu, Yandi Wu, Zhong Wu, An-Chih Wu, Jianhui Wu, Xiaoke Wu, Zhenguo Wu, Jason H Y Wu, Bing-Bing Wu, Yi-Mi Wu, Selena Meiyun Wu, M Wu, Hui-Mei Wu, Danni Wu, Minqing Wu, Sijie Wu, Geng-ze Wu, Kun Wu, Cheng-Hua Wu, Shaofei Wu, Zhaoyang Wu, Qihan Wu, Kunling Wu, R Ryanne Wu, Pei Wu, Hao Wu, Mingxuan Wu, Wendy Wu, Yukang Wu, Jingtao Wu, Douglas C Wu, Guizhen Wu, Zhangjie Wu, Lili Wu, Jianwu Wu, Min-Jiao Wu, Biaoliang Wu, Huan Wu, Shengxi Wu, Fei-Fei Wu, Peih-Shan Wu, Guoqing Wu, Yu-Yuan Wu, Pei-Yu Wu, Jing Wu, Geting Wu, Lun-Gang Wu, Dongzhe Wu, G Wu, Junlong Wu, Jia-Jun Wu, Jiangyue Wu, Muzhou Wu, Junzhu Wu, Ray-Chin Wu, Jian-Qiu Wu, T Wu, Jianxiong Wu, Liping Wu, Haiwei Wu, Guoping Wu, Yong-Hao Wu, Jin-hua Wu, Yi Wu, Chongming Wu, You Wu, Xudong Wu, Qunzheng Wu, Liqiang Wu, Cuiling Wu, Kunfang Wu, Limeng Wu, Jason Wu, Bian Wu, Zhibing Wu, Shuying Wu, Caihong Wu, Naqiong Wu, Huating Wu, Joseph C Wu, Tianhao Wu, Zhi-Hong Wu, Congying Wu, Gaojun Wu, Dongping Wu, Chiao-En Wu, Li Wu, Shaoxuan Wu, Haixia Wu, Yihang Wu, Gen Wu, Fanchang Wu, Xiaorong Wu, Jiahao Wu, Mingjie Wu, Mei Wu, Jiapei Wu, Lingqian Wu, Jia Wu, Fangge Wu, Sen-Chao Wu, Yanhui Wu, Zhiqiang Wu, Shugeng Wu, Sarah Wu, Dongmei Wu, Xuanqin Wu, Caiwen Wu, Junjing Wu, Jiangdong Wu, Guihua Wu, Meini Wu, Yingbiao Wu, Rui Wu, Hua-Yu Wu, Bifeng Wu, Jingwan Wu, Lingling Wu, Xinmiao Wu, Junzheng Wu, Yi-Fang Wu, Yuyi Wu, Yixuan Wu, Leilei Wu, Qinglin Wu, Bin Wu, Tianqi Wu, Shiya Wu, Hui-Chen Wu, Jian Wu, Sijun Wu, Cong Wu, Yiwen Wu, Feng Wu, Xi-Ze Wu, Qiuji Wu, Alexander T H Wu, Semon Wu, Qinan Wu, Lai Man Natalie Wu, Zhuokai Wu, Ran Wu, Panyun Wu, Kui Wu, Yumei Wu, Yueling Wu, Xinrui Wu, Biwei Wu, Xing Wu, Jiayi Wu, Hua Wu, Bingjie Wu, Yuen-Jung Wu, Xiaoliang Wu, Matthew A Wu, Jin Wu, Juanjuan Wu, Qiuhong Wu, Hongfu Wu, Xiaoming Wu, Ming-Sian Wu, Ronghua Wu, Junduo Wu, Dandan Wu, Yuliang Wu, Ming-Shiang Wu, Ying-Ying Wu, Chaoling Wu, Guang-Liang Wu, De Wu, Yihua Wu, Yuanyuan Wu, Tsung-Jui Wu, Yulian Wu, Han Wu, Lipeng Wu, Zhihao Wu, Jiexi Wu, Anna H Wu, Qiu Wu, Huazhen Wu, Yaqin Wu, Shengru Wu, Chieh-Lin Stanley Wu, Xiaoqian Wu, Xiahui Wu, Jian-Yi Wu, Jianli Wu, Yun-Wen Wu, Qiuya Wu, Tsai-Kun Wu, Xinyin Wu, Guoyao Wu, Zhenfeng Wu, Guoli Wu, J W Wu, Bill X Wu, Zujun Wu, Jianliang Wu, Yuanshun Wu, Ling-Ying Wu, Zeng-An Wu, Jianrong Wu, Xue Wu, Ke Wu, Mengxue Wu, Cheng-Yang Wu, Jinghong Wu, Rongrong Wu, Ruolan Wu, Rong Wu, Kevin Zl Wu, Xiaohong Wu, Run Wu, Zaihao Wu, Chaowei Wu, Yu-Ke Wu, Xinjing Wu, Anyue Wu, Shu Wu, Yun Wu, Xuan Wu, Meili Wu, Wanxia Wu, Yi-No Wu, Chao-Liang Wu, Chengwei Wu, Y-W Wu, Pensee Wu, Zhao-Bo Wu, Guangxian Wu, Xiao Wu, Juanli Wu, Xinlei Wu, Changjie Wu, Sai Wu, Yujuan Wu, Jiawei Wu, Haoze Wu, Renlv Wu, Yipeng Wu, Xiaoyang Wu, Yuh-Lin Wu, Yu'e Wu, Dan-Chun Wu, An-Hua Wu, Meng-Chao Wu, Yuanhao Wu, Jer-Yuarn Wu, Qian-Yan Wu, Guangyan Wu, Huisheng Wu, Huijuan Wu, Shuting Wu, Long-Jun Wu, Alice Ying-Jung Wu, Xiru Wu, Zhenfang Wu, Lidi Wu, Yetong Wu, Disheng Wu, Linmei Wu, Huiwen Wu, Zhenzhou Wu, Yuhong Wu, Liang Wu, Liyan Wu, Kuan-Li Wu, Pei-Ting Wu, Xiao-Jin Wu, Terence Wu, Lifeng Wu, Shujuan Wu, Gang Wu, Xue-Mei Wu, Szu-Hsien Wu, Yan-ling Wu, Xiaokang Wu, Lingyan Wu, Yih-Jer Wu, Xinghua Wu, Chunfu Wu, Yingxia Wu, Rongling Wu, Xifeng Wu, Jinhua Wu, Sihan Wu, Ming-Yue Wu, Shiyang Wu, K D Wu, Jinmei Wu, Luyan Wu, Shin-Long Wu, Zhipeng Wu, Shuai Wu, Guangzhen Wu, Zhixiang Wu, Longting Wu, Zhengsheng Wu, Xiaoqiong Wu, Yaoxing Wu, Yuqin Wu, Yudan Wu, Zoe Wu, Hongting Wu, Chi-Jen Wu, R Wu, Meina Wu, Zhongqiu Wu, Dengying Wu, Anke Wu, Cheng-Jang Wu, Hsi-Chin Wu, Shufang Wu, Yongjiang Wu, Yuan-de Wu, Sihui Wu, Qi Wu, Wenhui Wu, Fenfang Wu, K S Wu, Nana Wu, Jianzhi Wu, Lin-Han Wu, Jinjun Wu, Zhen Wu, Chen-Lu Wu, Haiyan Wu, Jing-Fang Wu, Yihui Wu, Qiqing Wu, Zhengzhi Wu, Dai-Chao Wu, Zhenyan Wu, Wen-Jeng Wu, Yongqun Wu, Guanming Wu, Sean M Wu, Hei-Man Wu, Su-Hui Wu, Diana H Wu, Ben J Wu, Pingxian Wu, Chew-Wun Wu, Yillin Wu, Jiang-Bo Wu, Xiaobing Wu, Jerry Wu, Siming Wu, Zijun Wu, Daqing Wu, Yu-Hsuan Wu, Lichao Wu, Zhimin Wu, Daxian Wu, Qijing Wu, Zhaoyi Wu, Z Wu, Tong Wu, Cheng-Chun Wu, Tracy Wu, Shusheng Wu, D Wu, Ting-Ting Wu, Xiao-Yan Wu, Lan Wu, J Wu, Changchen Wu, Qi-Fang Wu, Changwei Wu, Liangyan Wu, Liufeng Wu, Kan Wu, Mingming Wu, Eugenia Wu, Xiaolong Wu, Chunru Wu, Zhaofei Wu, Shenhao Wu, Li-Peng Wu, Yuna Wu, Minna Wu, Justin Che-Yuen Wu, Buling Wu, Chengyu Wu, Wutian Wu, Yuwei Wu, Guixin Wu, Haijing Wu, Hei Man Wu, Junfei Wu, Qiuchen Wu, Xiao-Hui Wu, Linyu Wu, Wenda Wu, Xiaofeng Wu, Yung-Fu Wu, Mengbo Wu, Zhenling Wu, Maoqing Wu, Zuping Wu, Chun-Chieh Wu, Julian Wu, Binbin Wu, Xiaohui Wu, Qian Wu, Xinchun Wu, Shuisheng Wu, Linxiang Wu, Xueqing Wu, Bo Wu, Moxin Wu, Xiao-Cheng Wu, Anzhou Wu, Shuyi Wu, Jiahui Wu, Meiqin Wu, Shihao Wu, Jer-Yuan Wu, Wen-Shu Wu, Wudelehu Wu, Ruonan Wu, Song Wu, Yulin Wu, De-Fu Wu, Hongyu Wu, Yurong Wu, Zixuan Wu, Shih-Ying Wu, Chih-Hsing Wu, Chengrong Wu, Yinghao Wu, Yuanzhao Wu, Wenjie Wu, Baochuan Wu, Ziliang Wu, Liuting Wu, Chia-Ling Wu, Y Q Wu, Man Wu, Na Wu, Wutain Wu, Chenyang Wu, Jinyu Wu, Selwin K Wu, Ping Wu, Lorna Wu, D I Wu, Yi-Cheng Wu, Jianzhong Wu, Xiaoyun Wu, Zhourui Wu, Li-Jun Wu, Xinhe Wu, Zhi-Wei Wu, Yinan Wu, Xinyan Wu, Xin Wu, Ting-Feng Wu, Yawei Wu, Shixin Wu, Hong-Mei Wu, Xiaojin Wu, Yiqun Wu, Tsung-Teh Wu, Jiarui Wu, Qi-Nian Wu, Ju Wu, Kai-Yue Wu, Pengjie Wu, Xi-Chen Wu, Zhe Wu, Shaoping Wu, Zhou Wu, Han-Jie Wu, Haijiang Wu, Weijie Wu, Hongfei Wu, Xiaojie Wu, Yi-Ying Wu, Zhentian Wu, Ze Wu, Kai-Hong Wu, Yuting Wu, Minyao Wu, Xueyan Wu, Shinan Wu, Feifei Wu, Yonghui Wu, Haoxuan Wu, Yanzhi Wu, Yiyi Wu, Dong Wu, Guohao Wu, Shibo Wu, Wenjing Wu, Wenqian Wu, Tian Wu, Hai-Yan Wu, Tiantian Wu, Chong Wu, Hongxian Wu, Daoyuan Wu, Zongfu Wu, Ling Wu, Yuxiang Wu, Xilong Wu, Yuyu Wu, Zong-Jia Wu, Huijian Wu, Fengming Wu, Guorong Wu, Chuanhong Wu, Choufei Wu, Chi-Chung Wu, Junfang Wu, Xingwei Wu, Ling-Fei Wu, Xiaoqing Wu, Xinyang Wu, Xiaomin Wu, Yili Wu, Hong-Fu Wu, Shao-Ming Wu, Thomas D Wu, Lizhen Wu, Yuanming Wu, Hsien-Ming Wu, Jian Hui Wu, Litong Wu, Yuxian Wu, Weihua Wu, Lei Wu, C Wu, Wei Wu, Yu-E Wu, Qiulian Wu, Mei-Hwan Wu, Yuexiu Wu, Shaoze Wu, Zilong Wu, Chi-Hao Wu, Baojin Wu, Chao Wu, Yao Wu, Ya Wu, Do-Bo Wu, Wenjun Wu, Zhongren Wu, Nini Wu, Michael C Wu, Ning Wu, Jie Wu, Ming J Wu, Yi-Syuan Wu, Zhenzhen Wu, Limei Wu, Tianwen Wu, Wen-Chieh Wu, Yunhua Wu, Junfeng Wu, Shunan Wu, Junqi Wu, Jianing Wu, Honglin Wu, Maureen Wu, Yexiang Wu, Yan-Hua Wu, Mengjun Wu, Y H Wu, Liuying Wu, Mingxing Wu, Xiaomeng Wu, Suhua Wu, Shyh-Jong Wu, Tung-Ho Wu, Hongliang Wu, Wenxian Wu, Xuekun Wu, Ed Xuekui Wu, Wenqiang Wu, Chuang Wu, Jingyi Wu, Duojiao Wu, Xueyuan Wu, Ji-Zhou Wu, Lianqian Wu, Gaige Wu, Qing-Qian Wu, Haihu Wu, Xiushan Wu, Xueyao Wu, Tingchun Wu, Yafei Wu, Lingxi Wu, R-J Wu, Weidong Wu, Re-Wen Wu, Zhidan Wu, Peiyao Wu, Xuemei Wu, Chen Wu, Yiting Wu, Kerui Wu, Lihong Wu, Shiqi Wu, Liren Wu, Xiuhua Wu, Beili Wu, Yongqi Wu, Ruihong Wu, Huini Wu, Lingyun Wu, Guang-Long Wu, Po-Chang Wu, Qinghua Wu, Ru-Zi Wu, Wenxue Wu, Wenlin Wu, Changjing Wu, Xiexing Wu, J Y Wu, Jianping Wu, Guanggeng Wu, W J Wu, Zhichong Wu, Di Wu, Shaoyu Wu, Xiaotong Wu, Junyong Wu, Hui Wu, Shengde Wu, Hongyan Wu, Mengyuan Wu, Yutong Wu, Zheming Wu, Yiping Wu, Dapeng Wu, Guiping Wu, Wen-Hui Wu, Bing Wu, Wen-Sheng Wu, Yunpeng Wu, Li-Ling Wu, Xiao-Yuan Wu, Baiyan Wu, Qiu-Li Wu, Ying Wu, Xiao-Ye Wu, Da-Hua Wu, Hsing-Chieh Wu, Hui-Xuan Wu, Chieh-Jen Wu, Pengning Wu, Sichen Wu, S F Wu, Mengying Wu, Jia-En Wu, Ming-Der Wu, Weida Wu, Qi-Jun Wu, Guo-Chao Wu, Zhenyong Wu, Qi-Biao Wu, Yangfeng Wu, Lijie Wu, Zhiye Wu, Jihui Wu, Zhengliang L Wu, Qianqian Wu, JieQian Wu, Jingyun Wu, Xiaoman Wu, Ruohao Wu, Yiyang Wu, Zhengfeng Wu, Xiao-Jun Wu, Lizi Wu, Qiang Wu, J-Z Wu, Guangjie Wu, Pengfei Wu, Jundong Wu, Jianying Wu, Meng-Ling Wu, Beier Wu, Jamie L Y Wu, Lingxiang Wu, Keija Wu, Xilin Wu, An-Li Wu, Yanhua Wu, Yi-Ming Wu, Chengbiao Wu, Huanghui Wu, Dong-Feng Wu, Kunsheng Wu, Zhengcan Wu, Yuxin Wu, Kun-Rong Wu, Dong-Fang Wu, Guanxian Wu, Guifen Wu, Sensen Wu, Yifeng Wu, Pin Wu, Tzu-Chun Wu, Qingping Wu, R M Wu, Mian Wu, S J Wu, Haisu Wu, Senquan Wu, Jingjing Wu, Cheng Wu, Meng Wu, Geping Wu, Yu Wu, Yumin Wu, Xia Wu, Xian-Run Wu, William Ka Kei Wu, Juan Wu, Pei-Ei Wu, Meng-Hsun Wu, Yingying Wu, S M Wu, Xiangwei Wu, Guangrun Wu, Yangyu Wu, Liuxin Wu, Jia-Hui Wu, Jin-Zhen Wu, S L Wu, Shaohuan Wu, June K Wu, Yanli Wu, Haishan Wu, H Wu, Zhou-Ming Wu, Deqing Wu, Tao Wu, Dong-Bo Wu, Binxin Wu, Yalan Wu, Xiangxin Wu, Xueji Wu, Hongxi Wu, Zhonghui Wu, Jiaxi Wu, Tianzhi Wu, Meiqi Wu, Weiwei Wu, Yan-Jun Wu, Lijuan Wu, Tingqin Wu, Jianming Wu, P L Wu, Yih-Ru Wu, Lanlan Wu, Jianjun Wu, Jianguang Wu, An-Xin Wu, Xingjie Wu, Jianzhang Wu, Xianan Wu, Wei-Ping Wu, Haoan Wu, Fang-Tzu Wu, Zhongjun Wu, Wenwen Wu, Xi Wu, Teng Wu, Xiaoling Wu, Mengjuan Wu, Wen Wu, Yifan Wu, Yang Wu, Qianhu Wu, Wu-Tian Wu, Shenyue Wu, Qianwen Wu, Ye Wu, Lixing Wu, Gui-Qin Wu, Grace F Wu, Xing-Ping Wu, Ming Wu, Lisha Wu, Yanchuan Wu, Siqi Wu, Yuming Wu, Yuan Wu, I H Wu, Yu-Ting Wu, Hailong Wu, Minghua Wu, B Wu, Zhenlong Wu, Fang Wu, Guanzhong Wu, Liqun Wu, Guifu Wu, Chris Y Wu, Zhikang Wu, Qi-Yong Wu, Qingshi Wu, Zhao-Yang Wu, Chih-Ching Wu, Man-Jing Wu, Jun Wu, Jinhui Wu, Jincheng Wu, Linhong Wu, Hung-Tsung Wu, Tangchun Wu, Xinglong Wu, Zhen-Yang Wu, Ma Wu, Yin Wu, Jiu-Lin Wu, Dongyan Wu, Yong Wu, Yan Wu, Weizhen Wu, Fanggeng Wu, Changyu Wu, Dishan Wu, Ge-ru Wu, Yue Wu, Yi-Long Wu, Jinqiao Wu, Jing-Wen Wu, Zhongyang Wu, Lifang Wu, Sheng-Li Wu, Songfen Wu, Jia-Wei Wu, Yihan Wu, Kebang Wu, Wenyong Wu, Cai-Qin Wu, Yilong Wu, Yanan Wu, Hsiu-Chuan Wu, Xueqian Wu, Paul W Wu, Yen-Wen Wu, Xing-De Wu, Ying-Ting Wu, Yucan Wu, Mingfu Wu, Na-Qiong Wu, Jinze Wu, Xuhan Wu, Linzhi Wu, H J Wu, Ruize Wu, Dirong Wu, Yaohong Wu, Chung-Yi Wu, Jianyi Wu, Jugang Wu, Jiao Wu, Liang-Huan Wu, Xueling Wu, Ruying Wu, Gen Sheng Wu, Zhaoyuan Wu, Shiwen Wu, Andong Wu, Hsan-Au Wu, Yu-Ling Wu, Jia-Qi Wu, Yanting Wu, Xihai Wu, Lulu Wu, Xuxian Wu, Xiaomei Wu, Jingyue Wu, Shuihua Wu, Ren Wu, S Wu, Yupeng Wu, Haoming Wu, Samuel M Wu, Fan Wu, Yuesheng Wu, Yihe Wu, Tiange Wu, Shuang Wu, Jiayu Wu, Chia-Lung Wu, Shengnan Wu, Yaojiong Wu, Zhuoze Wu, Y Wu, Y Y Wu, Zimu Wu, Depei Wu, Yi-Hua Wu, Haiyun Wu, Yanyan Wu, Min Wu, Wenjuan Wu, Guangxi Wu, Jinfeng Wu, Junjie Wu, Yawen Wu, Pinglian Wu, Hui-Hui Wu, Xunwei Wu, Xuefeng Wu, Depeng Wu, Constance Wu, Dianqing Wu, Qibiao Wu, Nan Wu, Hao-Tian Wu, Hanyu Wu, Xiaojiang Wu, Cheng-Jun Wu, San-pin Wu, Xiaofan Wu, Xiwei Wu, Shi-Xin Wu, Shao-Guo Wu, Sunyi Wu, Yueheng Wu, Chengqian Wu, Kuixian Wu, Xin-Xi Wu, Guanyi Wu, Qiuxia Wu, Danhong Wu, Zhong-Jun Wu, He Wu, Siyi Wu, Xiangsheng Wu, Kaili Wu, Liting Wu, Lanxiang Wu, Ping-Hsun Wu, Zheng Wu, Wen-Ling Wu, Jiang-Nan Wu, Huanlin Wu, Yongfei Wu, Catherine A Wu, Leslie Wu, Shuo Wu, Peng-Fei Wu, Meng-Han Wu, Cho-Kai Wu, Hon-Yen Wu, Yuguang Philip Wu, Anguo Wu, Hai-Yin Wu, Yicheng Wu, Xiaolang Wu, Yujie Wu, Qing Wu, V C Wu, Haomin Wu, Xingdong Wu, Hengyu Wu, Jiang Wu, Xiaoli Wu, Chengxi Wu, Junyi Wu, William K K Wu, Ling-qian Wu, Chun Wu, Lesley Wu, Niting Wu, Jiayuan Wu, Xueying Wu, Yingning Wu, S-F Wu, David Wu, Mei-Na Wu, Joshua L Wu, Jin-Shang Wu, Guanzhao Wu, Jianqiang Wu, Runda Wu, Li-Hsien Wu, Rongjie Wu, June-Hsieh Wu, Huazhang Wu, Huanwen Wu, Xiu-Zhi Wu, Yanran Wu, Xianfeng Wu, Weibin Wu, Xuanshuang Wu, Yan Yan Wu, G X Wu, Chien-Ting Wu, Runpei Wu, Jiaqi Wu, Li-Na Wu, Qinfeng Wu, Chia-Chang Wu, Yueming Wu, Renhai Wu, Siyu Wu, Baojian Wu, Yi-Xia Wu, Wei-Yin Wu, C-H Wu, Renrong Wu, Chuan-Ling Wu, Xinran Wu, Fengying Wu, Qiuliang Wu, Guanhui Wu, Jinjie Wu, Wei-Chi Wu, Wei-Xun Wu, Meng-Na Wu, Lin Wu, Wan-Fu Wu, Jiajing Wu, Colin Chih-Chien Wu, Yajie Wu, Qiaowei Wu, Yaru Wu, Xue-Yan Wu, Xiaoping Wu, Weijun Wu, Mengchao Wu, Boquan Wu, Chunyan Wu, Zelai Wu, Pei-Wen Wu, Guojun Wu, Yichen Wu, Ming-Tao Wu, Hsueh-Erh Wu, Guang-Bo Wu, Zhi-Yong Wu, Kay L H Wu, Chia-Zhen Wu, Yong-Hong Wu, Anping Wu, Jiahang Wu, Xiaobin Wu, Ching-Yi Wu, Linzhen Wu, Xiaoxing Wu, Haidong Wu, Zhen-Qi Wu, Mark N Wu, Guanrong Wu, Xianpei Wu, Jianmin Wu, An-Dong Wu, Yanchun Wu, Dongsheng Wu, Ren-Chin Wu, Yuchen Wu, Mengna Wu, Zhuanbin Wu, Lijun Wu, Yanjing Wu, Haodi Wu, Lun Wu, Si-Jia Wu, Yongfa Wu, Ximei Wu, Hai-Ping Wu, Xiangping Wu, Wenyu Wu, L-F Wu, Yixia Wu, Haiying Wu, Yiran Wu, Yanhong Wu, Xiayin Wu, Yali Wu, Yushun Wu, Qitian Wu, Qin Wu, Xiaofu Wu, Jiamei Wu, Xiaoyong Wu, Qiong Wu, Xiaoying Wu, Wujun Wu, Peiyi Wu, N Wu, Yongmei Wu, Xiaojing Wu, Yizhou Wu, Dan Wu, Wen-Qiang Wu, Anshi Wu, Junqing Wu, Xiao-Yang Wu, Zhaoxia Wu, Liyang Wu, Hongke Wu, Mengqiu Wu, Peng Wu, Haibin Wu, Ding Lan Wu, Kejia Wu, Lecheng Wu, Yingzhi Wu, Junshu Wu, Anyi Wu, Jianxin Wu, Deguang Wu, Jiaxuan Wu, W Wu, Justin C Y Wu, Jiong Wu, Yu-Chih Wu, Qinglan Wu, Xinyi Wu, Diana Wu, Zhongluan Wu, Xuefen Wu, Yanqiong Wu, Shengming Wu, Jian-Lin Wu, Donglin Wu, Daren Wu, Lintao Wu, Xiaodong Wu, Chang-Jiun Wu, Irene X Y Wu, Chunshuai Wu, Yaping Wu, Yangna Wu, Xiping Wu, Zongheng Wu, Chia-Chen Wu, Wenyi Wu, Yansheng Wu, Shaojun Wu, Aimin Wu, Caisheng Wu, Zhongchan Wu, Xu Wu, Yaohua Wu, Fei Wu, Yibo Wu, Qinyi Wu, Zhengyu Wu, Yadi Wu, Hang Wu, L Wu, Mingjun Wu, Yuetong Wu, Wen-Juan Wu, Guangming Wu, Lingzhi Wu, Tingting Wu, Zhuzhu Wu, Zhong-Yan Wu, Yuanbing Wu, Cuiyan Wu, Baoqin Wu, Colin O Wu, Shuyan Wu, Hongmei Wu, Guangsen Wu, Xiaolin Wu, An Guo Wu, Kailang Wu, Chien-Sheng Wu, Chun-Hua Wu, Jemma X Wu, Wenqi Wu, Quanhui Wu, Qing-Wu Wu, Yanxiang Wu, Jiajin Wu, Qiao Wu, Yuan Kai Wu
articles
Jared M Churko, Priyanka Garg, Barbara Treutlein +14 more · 2018 · Nature communications · Nature · added 2026-04-24
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have become a powerful tool for human disease modeling and therapeutic testing. However, their use remains limited by their immat Show more
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have become a powerful tool for human disease modeling and therapeutic testing. However, their use remains limited by their immaturity and heterogeneity. To characterize the source of this heterogeneity, we applied complementary single-cell RNA-seq and bulk RNA-seq technologies over time during hiPSC cardiac differentiation and in the adult heart. Using integrated transcriptomic and splicing analysis, more than half a dozen distinct single-cell populations were observed, several of which were coincident at a single time-point, day 30 of differentiation. To dissect the role of distinct cardiac transcriptional regulators associated with each cell population, we systematically tested the effect of a gain or loss of three transcription factors (NR2F2, TBX5, and HEY2), using CRISPR genome editing and ChIP-seq, in conjunction with patch clamp, calcium imaging, and CyTOF analysis. These targets, data, and integrative genomics analysis methods provide a powerful platform for understanding in vitro cellular heterogeneity. Show less
📄 PDF DOI: 10.1038/s41467-018-07333-4
HEY2
Lianjie Miao, Jingjing Li, Jun Li +13 more · 2018 · Scientific reports · Nature · added 2026-04-24
Hey2 gene mutations in both humans and mice have been associated with multiple cardiac defects. However, the currently reported localization of Hey2 in the ventricular compact zone cannot explain the Show more
Hey2 gene mutations in both humans and mice have been associated with multiple cardiac defects. However, the currently reported localization of Hey2 in the ventricular compact zone cannot explain the wide variety of cardiac defects. Furthermore, it was reported that, in contrast to other organs, Notch doesn't regulate Hey2 in the heart. To determine the expression pattern and the regulation of Hey2, we used novel methods including RNAscope and a Hey2 Show less
📄 PDF DOI: 10.1038/s41598-018-20917-w
HEY2
Kai-Hong Wu, Qian-Ru Xiao, Yu Yang +6 more · 2018 · Journal of molecular and cellular cardiology · Elsevier · added 2026-04-24
The objective of the study was to elucidate the mechanism by which microRNA-34a (miR-34a) influences heart development and participates in the pathogenesis of congenital heart disease (CHD) by targeti Show more
The objective of the study was to elucidate the mechanism by which microRNA-34a (miR-34a) influences heart development and participates in the pathogenesis of congenital heart disease (CHD) by targeting NOTCH-1 through the Notch signaling pathway. Forty D7 pregnant mice were recruited for the purposes of the study and served as the CHD (n=20, successfully established as CHD model) and normal (n=20) groups. The positive expression of the NOTCH-1 protein was evaluated by means of immunohistochemistry. Embryonic endocardial cells (ECCs) were assigned into the normal, blank, negative control (NC), miR-34a mimics, miR-34a inhibitors, miR-34a inhibitors+siRNA-NOTCH-1, siRNA-NOTCH-1, miR-34a mimics+NOTCH-1 OE and miR-34a mimics+crispr/cas9 (mutant NOTCH-1) groups. The expressions of miR-34a, NOTCH-1, Jagged1, Hes1, Hey2 and Csx in cardiac tissues and ECCs were determined by both RT-qPCR and western blotting methods. MTT assay and flow cytometry were conducted for cell proliferation and apoptosis measurement. A dual luciferase reporter assay was applied to demonstrate that NOTCH-1 was the target gene of miR-34a. In comparison to the normal group, the expressions of miR-34a, Jagged1, Hes1 and Hey2 displayed up-regulated levels, while the expressions of NOTCH-1 and Csx were down-regulated in the CHD group. Compared with the blank and NC groups, the miR-34a mimics and siRNA-NOTCH-1 groups displayed reduced expressions of NOTCH-1 and Csx as well as a decreased proliferation rate, higher miR-34a, Jagged1, Hes1 and Hey2 expressions and an increased rate of apoptosis; while an reverse trend was observed in the miR-34a inhibitors group. The expressions of MiR-34a recorded increased levels in the miR-34a mimics+NOTCH-1 OE and miR-34a mimics+crispr/cas9 (mutant NOTCH-1) groups, however no changes in the expressions of NOTCH-1, Jagged1, Hes1, Hey2, Csx, as well as cell proliferation and apoptosis were observed when compared to the blank and NC groups. The results of our study demonstrated that miR-34a increases the risk of CHD through its downregulation of NOTCH-1 by modulating the Notch signaling pathway. Show less
no PDF DOI: 10.1016/j.yjmcc.2017.11.015
HEY2
Lu Zhao, Song Wu, Erya Huang +3 more · 2018 · PloS one · PLOS · added 2026-04-24
Essential thrombocytosis (ET) is a chronic myeloproliferative disorder with an unregulated surplus of platelets. Complications of ET include stroke, heart attack, and formation of blood clots. Althoug Show more
Essential thrombocytosis (ET) is a chronic myeloproliferative disorder with an unregulated surplus of platelets. Complications of ET include stroke, heart attack, and formation of blood clots. Although platelet-enhancing mutations have been identified in ET cohorts, genetic networks causally implicated in thrombotic risk remain unestablished. In this study, we aim to identify novel ET-related miRNA-mRNA regulatory networks through comparisons of transcriptomes between healthy controls and ET patients. Four network discovery algorithms have been employed, including (a) Pearson correlation network, (b) sparse supervised canonical correlation analysis (sSCCA), (c) sparse partial correlation network analysis (SPACE), and, (d) (sparse) Bayesian network analysis-all through a combined data-driven and knowledge-based analysis. The result predicts a close relationship between an 8-miRNA set (miR-9, miR-490-5p, miR-490-3p, miR-182, miR-34a, miR-196b, miR-34b*, miR-181a-2*) and a 9-mRNA set (CAV2, LAPTM4B, TIMP1, PKIG, WASF1, MMP1, ERVH-4, NME4, HSD17B12). The majority of the identified variables have been linked to hematologic functions by a number of studies. Furthermore, it is observed that the selected mRNAs are highly relevant to ET disease, and provide an initial framework for dissecting both platelet-enhancing and functional consequences of dysregulated platelet production. Show less
📄 PDF DOI: 10.1371/journal.pone.0191932
HSD17B12
Di Wu, Xiang Tang, Li-Hua Gu +7 more · 2018 · CNS neuroscience & therapeutics · Blackwell Publishing · added 2026-04-24
Multiple evidence has indicated that myelin injury is common in Alzheimer's disease (AD). However, whether myelin injury is an early event in AD and the relationship between it and cognitive function Show more
Multiple evidence has indicated that myelin injury is common in Alzheimer's disease (AD). However, whether myelin injury is an early event in AD and the relationship between it and cognitive function is still elusive. Spatial memory of 5XFAD mice was determined by Morris water maze at 1 and 3 months old. Meanwhile, the deposition of Aβ, the expression of myelin basic protein (MBP), LINGO-1, NgR, and myelin ultrastructure in many memory-associated brain regions were detected in one-month-old and three-month-old mice (before and after LINGO-1 antibody administration) using immunostaining, Western blot (WB), and transmission electron microscopy (TEM), respectively. No abnormal Aβ deposition was found in one-month-old 5XFAD mice. However, spatial memory deficits were proved in accordance with an obvious demyelination in memory-associated brain regions in one-month-old mice and both deteriorated with age. Administration of LINGO-1 antibody could obviously restore the myelin impairments in CA1 and DG region and partially ameliorate spatial memory deficits. Our results demonstrated that myelin injury was an early event in 5XFAD mice even prior to emergence of deposition of Aβ. Intervention with the LINGO-1 antibody could attenuate impaired spatial memory deficits by remyelination, which suggested that myelin injury was involved in spatial memory deficits and remyelination may be a potential therapeutic strategy in early stage of AD or mild cognitive impairments. Show less
no PDF DOI: 10.1111/cns.12809
LINGO1
Xiaoqian Jing, Haoxuan Wu, Xi Cheng +6 more · 2018 · Scandinavian journal of gastroenterology · Taylor & Francis · added 2026-04-24
Colorectal cancer (CRC), one of the most aggressive gastrointestinal malignancies, is a frequently diagnosed life-threatening cancer worldwide. Most CRC patients have poor prognosis mainly because of Show more
Colorectal cancer (CRC), one of the most aggressive gastrointestinal malignancies, is a frequently diagnosed life-threatening cancer worldwide. Most CRC patients have poor prognosis mainly because of frequent metastasis and recurrence. Thus, it is crucial to find out some new biomarkers and to show deeper insights into the mechanisms of CRC. MLLT10, Myeloid/lymphoid or mixed-lineage leukemia translocated to 10, also known as AF10, a recurrent MLL partner. In this study, we found that MLLT10 promotes CRC tumor invasion and metastasis both in vitro and in vivo. Here, the expression of MLLT10 was evaluated by immunohistochemistry. Then, the plasmid and lentivirus particles for MLLT10 overexpression or knockdown were designed and constructed into SW620 and HT29 cells. Finally, cell proliferation assay, cell adhesion assay, transwell migration, and invasion assay were used to detect the migration and invasion ability of MLLT10 in CRC cells. A tail vein injection assay was employed to evaluate the role of MLLT10 in tumor metastases. MLLT10 expression was significantly higher in CRC tissues than in noncancerous tissues and was associated with some clinicopathological factors. In vitro, the overexpression of MLLT10 promoted CRC cell migration and invasion, while after MLLT10 was knocked down, the opposite results were observed. Furthermore, we used animal metastasis models to detect the function of MLLT10 in vivo, the results are same with the outcomes in vitro. In lung metastasis sites, the knockdown of MLLT10 in SW620 cells significantly inhibited Vimentin expression, whereas the E-Cadherin was increased. These results indicate that MLLT10 regulates the metastasis of CRC cells via EMT. Show less
no PDF DOI: 10.1080/00365521.2018.1481521
MLLT10
Jing Li, Qiong Zhang, Weiwei Zeng +5 more · 2018 · Molecular therapy. Nucleic acids · Elsevier · added 2026-04-24
Type 2 diabetes (T2D) is generally regarded as a metabolic disorder disease with various phenotypic expressions. Traditional Chinese medicine (TCM) has been widely used for preventing and treating dia Show more
Type 2 diabetes (T2D) is generally regarded as a metabolic disorder disease with various phenotypic expressions. Traditional Chinese medicine (TCM) has been widely used for preventing and treating diabetes. In our study, we demonstrated that Cyclocarya paliurus formula extractum (CPE), a compound of TCM, can ameliorate diabetes in diabetic rats. Transcriptome profiles were performed to elucidate the anti-diabetic mechanisms of CPE on pancreas and liver. Pancreatic transcriptome analysis showed CPE treatment significantly inhibited gene expressions related to inflammation and apoptosis pathways, among which the transcription factors (TFs) nuclear factor κB (NF-κB), STAT, and miR-9a/148/200 may serve as core regulators contributing to ameliorate diabetes. Biochemical studies also demonstrated CPE treatment decreased pro-inflammatory cytokines (tumor necrosis factor alpha [TNF-α], interleukin [IL]-1β, and IL-6) and reduced β cell apoptosis. In liver tissue, our transcriptome and biochemical experiments showed that CPE treatment reduced lipid accumulation and liver injury, and it promoted glycogen synthesis, which may be regulated by TFs Srebf1, Mlxipl, and miR-122/128/192. Taken together, our findings revealed CPE could be used as a potential therapeutic agent to prevent and treat diabetes. It is the first time to combine transcriptome and regulatory network analyses to study the mechanism of CPE in preventing diabetes, giving a demonstration of exploring the mechanism of TCM on complex diseases. Show less
📄 PDF DOI: 10.1016/j.omtn.2018.09.024
MLXIPL
Cheng-Yang Wu, Shih-Chia Tso, Jacinta L Chuang +7 more · 2018 · Molecular metabolism · Elsevier · added 2026-04-24
Mitochondrial pyruvate dehydrogenase kinases 1-4 (PDKs1-4) negatively regulate activity of the pyruvate dehydrogenase complex (PDC) by reversible phosphorylation. PDKs play a pivotal role in maintaini Show more
Mitochondrial pyruvate dehydrogenase kinases 1-4 (PDKs1-4) negatively regulate activity of the pyruvate dehydrogenase complex (PDC) by reversible phosphorylation. PDKs play a pivotal role in maintaining energy homeostasis and contribute to metabolic flexibility by attenuating PDC activity in various mammalian tissues. Cumulative evidence has shown that the up-regulation of PDK4 expression is tightly associated with obesity and diabetes. In this investigation, we test the central hypothesis that PDKs1-4 are a pharmacological target for lowering glucose levels and restoring insulin sensitivity in obesity and type 2 diabetes (T2D). Diet-induced obese (DIO) mice were treated with a liver-specific pan-PDK inhibitor 2-[(2,4-dihydroxyphenyl) sulfonyl]isoindoline-4,6-diol (PS10) for four weeks, and results compared with PDK2/PDK4 double knockout (DKO) mice on the same high fat diet (HFD). Both PS10-treated DIO mice and HFD-fed DKO mice showed significantly improved glucose, insulin and pyruvate tolerance, compared to DIO controls, with lower plasma insulin levels and increased insulin signaling in liver. In response to lower glucose levels, phosphorylated AMPK in PS10-treated DIO and HFD-fed DKO mice is upregulated, accompanied by decreased nuclear carbohydrate-responsive element binding protein (ChREBP). The reduced ChREBP signaling correlates with down-regulation of hepatic lipogenic enzymes (ACC1, FAS, and SCD1), leading to markedly diminished hepatic steatosis in both study groups, with lower circulating cholesterol and triacylglyceride levels as well as reduced fat mass. PS10-treated DIO as well as DKO mice showed predominant fatty acid over glucose oxidation. However, unlike systemic DKO mice, increased hepatic PDC activity alone in PS10-treated DIO mice does not raise the plasma total ketone body level. Our findings establish that specific targeting of hepatic PDKs with the PDK inhibitor PS10 is an effective therapeutic approach to maintaining glucose and lipid homeostasis in obesity and T2D, without the harmful ketoacidosis associated with systemic inhibition of PDKs. Show less
📄 PDF DOI: 10.1016/j.molmet.2018.03.014
MLXIPL
Hiroyuki Niwa, Katsumi Iizuka, Takehiro Kato +5 more · 2018 · Nutrients · MDPI · added 2026-04-24
The regulation of hepatic very-low-density lipoprotein (VLDL) secretion plays an important role in the pathogenesis of dyslipidemia and fatty liver diseases. VLDL is controlled by hepatic microsomal t Show more
The regulation of hepatic very-low-density lipoprotein (VLDL) secretion plays an important role in the pathogenesis of dyslipidemia and fatty liver diseases. VLDL is controlled by hepatic microsomal triglyceride transfer protein (MTTP). Show less
📄 PDF DOI: 10.3390/nu10030321
MLXIPL
Chaoxia Lu, Wei Wu, Fang Liu +9 more · 2018 · Journal of translational medicine · BioMed Central · added 2026-04-24
Cardiomyopathies are the most common clinical and genetic heterogeneity cardiac diseases, and genetic contribution in particular plays a major role in patients with primary cardiomyopathies. The aim o Show more
Cardiomyopathies are the most common clinical and genetic heterogeneity cardiac diseases, and genetic contribution in particular plays a major role in patients with primary cardiomyopathies. The aim of this study is to investigate cases of inherited cardiomyopathy (IC) for potential disease-causing mutations in 64 genes reported to be associated with IC. A total of 110 independent cases or families diagnosed with various primary cardiomyopathies, including hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, left ventricular non-compaction, and undefined cardiomyopathy, were collected after informed consent. A custom designed panel, including 64 genes, was screened using next generation sequencing on the Ion Torrent PGM platform. The best candidate disease-causing variants were verified by Sanger sequencing. A total of 78 variants in 73 patients were identified. After excluding the variants predicted to be benign and VUS, 26 pathogenic or likely pathogenic variants were verified in 26 probands (23.6%), including a homozygous variant in the SLC25A4 gene. Of these variants, 15 have been reported in the Human Gene Mutation Database or ClinVar database, while 11 are novel. The majority of variants were observed in the MYH7 (8/26) and MYBPC3 (6/26) gene. Titin (TTN) truncating mutations account for 13% in our dilated cardiomyopathy cases (3/23). This study provides an overview of the genetic aberrations in this cohort of Chinese IC patients and demonstrates the power of next generation sequencing in IC. Genetic results can provide precise clinical diagnosis and guidance regarding medical care for some individuals. Show less
no PDF DOI: 10.1186/s12967-018-1605-5
MYBPC3
Alex C Y Chang, Andrew C H Chang, Anna Kirillova +15 more · 2018 · Proceedings of the National Academy of Sciences of the United States of America · National Academy of Sciences · added 2026-04-24
This study demonstrates that significantly shortened telomeres are a hallmark of cardiomyocytes (CMs) from individuals with end-stage hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy (DCM) Show more
This study demonstrates that significantly shortened telomeres are a hallmark of cardiomyocytes (CMs) from individuals with end-stage hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy (DCM) as a result of heritable defects in cardiac proteins critical to contractile function. Positioned at the ends of chromosomes, telomeres are DNA repeats that serve as protective caps that shorten with each cell division, a marker of aging. CMs are a known exception in which telomeres remain relatively stable throughout life in healthy individuals. We found that, relative to healthy controls, telomeres are significantly shorter in CMs of genetic HCM and DCM patient tissues harboring pathogenic mutations: Show less
no PDF DOI: 10.1073/pnas.1714538115
MYBPC3
Ning Ma, Joe Z Zhang, Ilanit Itzhaki +11 more · 2018 · Circulation · added 2026-04-24
The progression toward low-cost and rapid next-generation sequencing has uncovered a multitude of variants of uncertain significance (VUS) in both patients and asymptomatic "healthy" individuals. A VU Show more
The progression toward low-cost and rapid next-generation sequencing has uncovered a multitude of variants of uncertain significance (VUS) in both patients and asymptomatic "healthy" individuals. A VUS is a rare or novel variant for which disease pathogenicity has not been conclusively demonstrated or excluded, and thus cannot be definitively annotated. VUS, therefore, pose critical clinical interpretation and risk-assessment challenges, and new methods are urgently needed to better characterize their pathogenicity. To address this challenge and showcase the uncertainty surrounding genomic variant interpretation, we recruited a "healthy" asymptomatic individual, lacking cardiac-disease clinical history, carrying a hypertrophic cardiomyopathy (HCM)-associated genetic variant (NM₀₀₀₂₅₈.2:c.170C>A, NP₀₀₀₂₄₉.1:p.Ala57Asp) in the sarcomeric gene MYL3, reported by the ClinVar database to be "likely pathogenic." Human-induced pluripotent stem cells (iPSCs) were derived from the heterozygous VUS MYL3 The heterozygous VUS MYL3 Our study illustrates the ability of clustered regularly interspaced short palindromic repeats/Cas9 genome-editing of carrier-specific iPSCs to elucidate both benign and pathogenic HCM functional phenotypes in a carrier-specific manner in a dish. As such, this platform represents a promising VUS risk-assessment tool that can be used for assessing HCM-associated VUS specifically, and VUS in general, and thus significantly contribute to the arsenal of precision medicine tools available in this emerging field. Show less
no PDF DOI: 10.1161/CIRCULATIONAHA.117.032273
MYBPC3
Xinxin Tian, Hui Zhang, Yali Zhao +8 more · 2018 · Environmental science and pollution research international · Springer · added 2026-04-24
Chromium (Cr) is one of the most important environmental pollutants which are released into the environment due to their wide usage in numerous industries. The excess of Cr (VI) can induce hepatotoxic Show more
Chromium (Cr) is one of the most important environmental pollutants which are released into the environment due to their wide usage in numerous industries. The excess of Cr (VI) can induce hepatotoxicity, while the molecular mechanism that is involved in Cr (VI)-induced hepatotoxicity is unclear. We demonstrated the induction of chromium poisoning model in chickens to identify the differentially expressed genes (DEGs), and their functions were analyzed under different physiological and pathological conditions. Histopathological examination and transcriptome data for chromium-poisoned livers and control livers were annotated with Illumina® HiSeq 2000. The histopathological examination in chromium poisoning groups showed diapedesis, hemolysis, degeneration, nucleus pycnosis, and central phlebectasia in the liver. A total of 334 genes were upregulated and 509 genes were downregulated. The most strongly upregulated genes were HKDC1, DDX4, ACACA, FDFT1, CYYR1, PPP1R3C, and SLC16A14, while the most downregulated genes were MYBPC3, CCKAR, PCK1, and CPT1A. A Gene Ontology (GO) term with the highest enrichment of DEGs is small molecule metabolic process. In cell component domain, the term with the highest enrichment is extracellular matrix. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways showed that glucose metabolism, lipid metabolism, and protein metabolism were the most important metabolic pathways in the liver. The current study first time provides important clues and evidence for identifying the differentially expressed genes in livers due to Cr (VI)-induced liver injury in chickens. Show less
no PDF DOI: 10.1007/s11356-018-1653-7
MYBPC3
Yu-Kun Li, Yuan-Jie Xie, Dai-Chao Wu +3 more · 2018 · International journal of oncology · added 2026-04-24
The novel neurite outgrowth inhibitor B (Nogo‑B) receptor (NgBR) is specific for Nogo‑B, which is highly expressed in various human organs and cells, including the lung, liver, kidney, smooth muscle c Show more
The novel neurite outgrowth inhibitor B (Nogo‑B) receptor (NgBR) is specific for Nogo‑B, which is highly expressed in various human organs and cells, including the lung, liver, kidney, smooth muscle cells, blood vessel endothelial cells and inflammatory cells. Previous studies have indicated that NgBR directly interacts with Nogo‑B and is able to independently influence lipid and cholesterol homeostasis, angiogenesis, N‑glycosylation, the epithelial-mesenchymal transition, the chemotaxis of endothelial cells and cellular proliferation and apoptosis. These multiple functions and actions of this receptor provide an understanding of the important roles of NgBR in various conditions, including fatty liver, atherosclerosis, intracranial microaneurysms, retinitis pigmentosa and severe neurological impairment. Furthermore, NgBR has been demonstrated to exert protean, multifunctional and enigmatic effects in cancer. The present review summarizes the latest knowledge on the suppressing and activating effects of NgBR, emphasizing its function in cancer. Further basic and medical research on this receptor may provide novel insight into its clinical implications on the prognosis of relevant human cancer types. Show less
no PDF DOI: 10.3892/ijo.2018.4520
NR1H3
Jing Tian, Jiaxi Wu, Xiang Chen +4 more · 2018 · eLife · added 2026-04-24
In obesity, elevated insulin causes fatty liver by activating the gene encoding SREBP-1c, a transcription factor that enhances fatty acid synthesis. Two transcription factors, LXRα and C/EBPβ, are nec Show more
In obesity, elevated insulin causes fatty liver by activating the gene encoding SREBP-1c, a transcription factor that enhances fatty acid synthesis. Two transcription factors, LXRα and C/EBPβ, are necessary but not sufficient for insulin induction of hepatic SREBP-1c mRNA. Here, we show that a third transcription factor, BHLHE40, is required. Immunoprecipitation revealed that BHLHE40 binds to C/EBPβ and LXRα in livers of rats that had fasted and then refed. Hepatic BHLHE40 mRNA rises rapidly when fasted rats are refed and when rat hepatocytes are incubated with insulin. Preventing this rise by gene knockout in mice or siRNAs in hepatocytes reduces the insulin-induced rise in SREBP-1c mRNA. Although BHLHE40 is necessary for insulin induction of SREBP-1c, it is not sufficient as demonstrated by failure of lentiviral BHLHE40 overexpression to increase hepatocyte SREBP-1c mRNA in the absence of insulin. Thus, an additional event is required for insulin to increase SREBP-1c mRNA. Show less
no PDF DOI: 10.7554/eLife.36826
NR1H3
Jie Ni, Lei-Lei Zhou, Li Ding +9 more · 2018 · Cancer medicine · Wiley · added 2026-04-24
The development of acquired EGFR-TKI therapeutic resistance is still a serious clinical problem in the management of lung adenocarcinoma. Peroxisome proliferator activated receptor gamma (PPARγ) agoni Show more
The development of acquired EGFR-TKI therapeutic resistance is still a serious clinical problem in the management of lung adenocarcinoma. Peroxisome proliferator activated receptor gamma (PPARγ) agonists may exhibit anti-tumor activity by transactivating genes which are closely associated with cell proliferation, apoptosis, and differentiation. However, it remains not clear whether efatutazone has similar roles in lung adenocarcinoma cells of gefitinib resistant such as HCC827-GR and PC9-GR. It has been demonstrated by us that efatutazone prominently increased the mRNA and protein expression of PPARγ, liver X receptor alpha (LXRα),as well as ATP binding cassette subfamily A member 1 (ABCA1). In the presence of GW9662 (a specific antagonist of PPARγ) or GGPP (a specific antagonist of LXRα), efatutazone (40 μmol/L) restored the proliferation of both HCC827-GR and PC9-GR cells and obviously inhibited the increased protein and mRNA expression of PPAR-gamma, LXR-alpha, and ABCA1 induced by efatutazone. LXRα knockdown by siRNA (si-LXRα) significantly promoted the HCC827-GR and PC9-GR cells proliferation, whereas incubation efatutazone with si-LXRα restored the proliferation ability compared with the control group. In addition, combination of efatutazone and LXRα agonist T0901317 showed a synergistic therapeutic effect on lung adenocarcinoma cell proliferation and PPAR gamma, LXR A and ABCA1 protein expression. These results indicate that efatutazone could inhibit the cells proliferation of HCC827-GR and PC9-GR through PPARγ/LXRα/ABCA1 pathway, and synergistic therapeutic effect is achieved when combined with T0901317. Show less
no PDF DOI: 10.1002/cam4.1440
NR1H3
Harilaos Filippakis, Amine Belaid, Brian Siroky +6 more · 2018 · Scientific reports · Nature · added 2026-04-24
Tuberous Sclerosis Complex (TSC), a rare genetic disorder with mechanistic target of rapamycin complex 1 (mTORC1) hyperactivation, is characterized by multi-organ hamartomatous benign tumors including Show more
Tuberous Sclerosis Complex (TSC), a rare genetic disorder with mechanistic target of rapamycin complex 1 (mTORC1) hyperactivation, is characterized by multi-organ hamartomatous benign tumors including brain, skin, kidney, and lung (Lymphangioleiomyomatosis). mTORC1 hyperactivation drives metabolic reprogramming including glucose and glutamine utilization, protein, nucleic acid and lipid synthesis. To investigate the mechanisms of exogenous nutrients uptake in Tsc2-deficient cells, we measured dextran uptake, a polysaccharide internalized via macropinocytosis. Tsc2-deficient cells showed a striking increase in dextran uptake (3-fold, p < 0.0001) relative to Tsc2-expressing cells, which was decreased (3-fold, p < 0.0001) with mTOR inhibitor, Torin1. Pharmacologic and genetic inhibition of the lipid kinase Vps34 markedly abrogated uptake of Dextran in Tsc2-deficient cells. Macropinocytosis was further increased in Tsc2-deficient cells that lack autophagic mechanisms, suggesting that autophagy inhibition leads to dependence on exogenous nutrient uptake in Tsc2-deficient cells. Treatment with a macropinocytosis inhibitor, ethylisopropylamiloride (EIPA), resulted in selective growth inhibition of Atg5-deficient, Tsc2-deficient cells (50%, p < 0.0001). Genetic inhibition of autophagy (Atg5 Show less
no PDF DOI: 10.1038/s41598-018-32256-x
PIK3C3
Shaoyang Zhao, Jianhong Xia, Xiuhua Wu +10 more · 2018 · Nature communications · Nature · added 2026-04-24
The class III PI3-kinase (PIK3C3) is an enzyme responsible for the generation of phosphatidylinositol 3-phosphate (PI3P), a critical component of vesicular membrane. Here, we report that PIK3C3 defici Show more
The class III PI3-kinase (PIK3C3) is an enzyme responsible for the generation of phosphatidylinositol 3-phosphate (PI3P), a critical component of vesicular membrane. Here, we report that PIK3C3 deficiency in zebrafish results in intestinal injury and inflammation. In pik3c3 mutants, gut tube forms but fails to be maintained. Gene expression analysis reveals that barrier-function-related inflammatory bowel disease (IBD) susceptibility genes (e-cadherin, hnf4a, ttc7a) are suppressed, while inflammatory response genes are stimulated in the mutants. Histological analysis shows neutrophil infiltration into mutant intestinal epithelium and the clearance of gut microbiota. Yet, gut microorganisms appear dispensable as mutants cultured under germ-free condition have similar intestinal defects. Mechanistically, we show that PIK3C3 deficiency suppresses the formation of PI3P and disrupts the polarized distribution of cell-junction proteins in intestinal epithelial cells. These results not only reveal a role of PIK3C3 in gut homeostasis, but also provide a zebrafish IBD model. Show less
no PDF DOI: 10.1038/s41467-018-05105-8
PIK3C3
Christopher R Bodle, Josephine H Schamp, Joseph B O'Brien +4 more · 2018 · SLAS discovery : advancing life sciences R & D · SAGE Publications · added 2026-04-24
Regulator of G protein signaling (RGS) proteins temporally regulate heterotrimeric G protein signaling cascades elicited by G protein-coupled receptor activation and thus are essential for cell homeos Show more
Regulator of G protein signaling (RGS) proteins temporally regulate heterotrimeric G protein signaling cascades elicited by G protein-coupled receptor activation and thus are essential for cell homeostasis. The dysregulation of RGS protein expression has been linked to several pathologies, spurring discovery efforts to identify small-molecule inhibitors of these proteins. Presented here are the results of a high-throughput screening (HTS) campaign targeting RGS17, an RGS protein reported to be inappropriately upregulated in several cancers. A screen of over 60,000 small molecules led to the identification of five hit compounds that inhibit the RGS17-Gα Show less
no PDF DOI: 10.1177/2472555217752301
RGS17
Hui-Chen Wu, Catherine Do, Irene L Andrulis +13 more · 2018 · Epigenetics · Taylor & Francis · added 2026-04-24
Family history, a well-established risk factor for breast cancer, can have both genetic and environmental contributions. Shared environment in families as well as epigenetic changes that also may be i Show more
Family history, a well-established risk factor for breast cancer, can have both genetic and environmental contributions. Shared environment in families as well as epigenetic changes that also may be influenced by shared genetics and environment may also explain familial clustering of cancers. Epigenetic regulation, such as DNA methylation, can change the activity of a DNA segment without a change in the sequence; environmental exposures experienced across the life course can induce such changes. However, genetic-epigenetic interactions, detected as methylation quantitative trait loci (mQTLs; a.k.a. meQTLs) and haplotype-dependent allele-specific methylation (hap-ASM), can also contribute to inter-individual differences in DNA methylation patterns. To identify differentially methylated regions (DMRs) associated with breast cancer susceptibility, we examined differences in white blood cell DNA methylation in 29 candidate genes in 426 girls (ages 6-13 years) from the LEGACY Girls Study, 239 with and 187 without a breast cancer family history (BCFH). We measured methylation by targeted massively parallel bisulfite sequencing (bis-seq) and observed BCFH DMRs in two genes: ESR1 (Δ4.9%, P = 0.003) and SEC16B (Δ3.6%, P = 0.026), each of which has been previously implicated in breast cancer susceptibility and pubertal development. These DMRs showed high inter-individual variability in methylation, suggesting the presence of mQTLs/hap-ASM. Using single nucleotide polymorphisms data in the bis-seq amplicon, we found strong hap-ASM in SEC16B (with allele specific-differences ranging from 42% to 74%). These findings suggest that differential methylation in genes relevant to breast cancer susceptibility may be present early in life, and that inherited genetic factors underlie some of these epigenetic differences. Show less
no PDF DOI: 10.1080/15592294.2018.1435243
SEC16B
Xiupeng Zhang, Guiyang Jiang, Jingjing Wu +5 more · 2018 · Oncology letters · added 2026-04-24
Zinc finger protein 668 (ZNF668) is a recently discovered protein and its expression levels, as well as its involvement in the invasion and metastasis of non-small cell lung cancer (NSCLC), are largel Show more
Zinc finger protein 668 (ZNF668) is a recently discovered protein and its expression levels, as well as its involvement in the invasion and metastasis of non-small cell lung cancer (NSCLC), are largely unknown. In the present study, immunohistochemical analysis demonstrated that ZNF668 protein expression was decreased in lung tumors (51/167, 30.5%) compared with adjacent normal lung tissues (43/62, 69.4%; P<0.001). Subsequent statistical analysis revealed that ZNF668 expression was negatively associated with increased tumor-node-metastasis stage (P=0.019) and lymph node metastasis (P=0.002). Following ZNF668 downregulation by transfection of a Show less
no PDF DOI: 10.3892/ol.2018.7802
ZNF668
Xiaofeng Xu, Yirun Li, Yi Huang +10 more · 2018 · Anatolian journal of cardiology · added 2026-04-24
Coronary heart disease (CHD) is the most common cause of death worldwide. This study aimed to validate the association of the rs964184 polymorphism with the CHD risk and included 874 CHD patients and Show more
Coronary heart disease (CHD) is the most common cause of death worldwide. This study aimed to validate the association of the rs964184 polymorphism with the CHD risk and included 874 CHD patients and 776 controls. rs964184 polymorphism genotyping was performed using Tm-shift polymerase chain reaction. A strong association of the rs964184 polymorphism with CHD was found (genotype: X Our results indicate that both gender and age have great impacts on the association of the rs964184 polymorphism with CHD among Chinese. Show less
no PDF DOI: 10.14744/AnatolJCardiol.2017.8002
ZPR1
H Wu, X-Y Zhang, Z Hu +10 more · 2017 · Oncogene · Nature · added 2026-04-24
Recently single-cell whole-exome sequencing (scWES) has deeply expanded and sharpened our knowledge of cancer evolution and subclonality. Herein, with scWES and matched bulk whole-exome sequencing (bu Show more
Recently single-cell whole-exome sequencing (scWES) has deeply expanded and sharpened our knowledge of cancer evolution and subclonality. Herein, with scWES and matched bulk whole-exome sequencing (bulk WES) on two colorectal cancer (CRC) patients with normal or adenomatous polyps, we found that both the adenoma and cancer were of monoclonal origin, and both shared partial mutations in the same signaling pathways, but each showed a specific spectrum of heterogeneous somatic mutations. In addition, the adenoma and cancer further developed intratumor heterogeneity with the accumulation of nonrandom somatic mutations specifically in GPCR, PI3K-Akt and FGFR signaling pathways. We identified novel driver mutations that developed during adenoma and cancer evolution, particularly in OR1B1 (GPCR signaling pathway) for adenoma evolution, and LAMA1 (PI3K-Akt signaling pathway) and ADCY3 (FGFR signaling pathway) for CRC evolution. In summary, we demonstrated that both colorectal adenoma and CRC are monoclonal in origin, and the CRCs further diversified into different subclones with heterogeneous mutation profiles accumulating in GPCR, PI3K-Akt and FGFR signaling pathways. ScWES provides evidence for the importance of mutations in certain pathways that would not be as apparent from bulk sequencing of tumors, and can potentially establish whether specific mutations are mutually exclusive or occur sequentially in the same subclone of cells. Show less
no PDF DOI: 10.1038/onc.2016.438
ADCY3
Bo Li, Ming Qian, Hao Cao +7 more · 2017 · Oncotarget · Impact Journals · added 2026-04-24
Although emerging studies have implicated that Aiopoietin-like 4 Protein (ANGPTL4) is related to the aggressiveness and metastasis of many tumors, the role of ANGPLT4 in giant cell tumor (GCT) of bone Show more
Although emerging studies have implicated that Aiopoietin-like 4 Protein (ANGPTL4) is related to the aggressiveness and metastasis of many tumors, the role of ANGPLT4 in giant cell tumor (GCT) of bone was rarely investigated. The mechanism of ANGPLT4 in tumor-induced osteoclastogenesis still remains unclear. In this study, we first demonstrated that ANGPTL4 was highly expressed in GCT compared to normal tissues, while we showed that TGF-β2 released by osteoclasts induced bone resorption could increase the expression of ANGPTL4 in GCTSCs. By using the luciferase reporter assay, we found that two downstreams of TGF-β2, Smad3 and Smad4, could directly activate the promoter of ANGPTL4, which might explain the mechanism of TGF-β2-induced ANGPLT4 expression. Moreover, knockout of ANGPTL4 by TALENs in GCTSCs inhibited tumor growth, angiogenesis and osteoclastogenesis in GCT Show less
📄 PDF DOI: 10.18632/oncotarget.18629
ANGPTL4
Allison E McQueen, Deepthi Kanamaluru, Kimberly Yan +8 more · 2017 · The Journal of biological chemistry · American Society for Biochemistry and Molecular Biology · added 2026-04-24
Angptl4 (Angiopoietin-like 4) is a circulating protein secreted by white and brown adipose tissues and the liver. Structurally, Angptl4 contains an N-terminal coiled-coil domain (CCD) connected to a C Show more
Angptl4 (Angiopoietin-like 4) is a circulating protein secreted by white and brown adipose tissues and the liver. Structurally, Angptl4 contains an N-terminal coiled-coil domain (CCD) connected to a C-terminal fibrinogen-like domain (FLD) via a cleavable linker, and both full-length Angptl4 and its individual domains circulate in the bloodstream. Angptl4 inhibits extracellular lipoprotein lipase (LPL) activity and stimulates the lipolysis of triacylglycerol stored by adipocytes in the white adipose tissue (WAT). The former activity is furnished by the CCD, but the Angptl4 domain responsible for stimulating adipocyte lipolysis is unknown. We show here that the purified FLD of Angptl4 is sufficient to stimulate lipolysis in mouse primary adipocytes and that increasing circulating FLD levels in mice through adenovirus-mediated overexpression (Ad-FLD) not only induces WAT lipolysis Show less
no PDF DOI: 10.1074/jbc.M117.803973
ANGPTL4
Zhonghong Wei, Yunlong Shan, Li Tao +7 more · 2017 · Molecular carcinogenesis · Wiley · added 2026-04-24
Intratumoral hypoxia promotes the distant metastasis of cancer subclones. The clinical expression level of hypoxia-inducible factor-1α (HIF-1α) reflects the prognosis of a variety of cancers, especial Show more
Intratumoral hypoxia promotes the distant metastasis of cancer subclones. The clinical expression level of hypoxia-inducible factor-1α (HIF-1α) reflects the prognosis of a variety of cancers, especially breast cancer. Histone deacetylase (HDAC) inhibitors can target HIF-1α protein due to von Hippel-Lindau (VHL) protein-dependent degradation. Dietary organosulfur compounds, such as those in garlic, have been reported as HDAC inhibitors. The effects of diallyl sulfide (DAS), diallyl disulfide (DADS), and diallyl trisulfide (DATS) on the ratio of firefly/Renilla luciferase activity in hypoxic MDA-MB-231 cells were determined. The mRNA expressions of HIF-1α target genes ANGPTL4, LOXL4, and LOX in hypoxic MDA-MB-231 cells were significantly down-regulated by DATS. DATS attenuated the metastatic potential of MDA-MB-231 cells in hypoxia-induced embryonic zebrafish, xenograft, and orthotopic tumors. Endothelial cell-cancer cell adhesion, wound healing, transwell, and tube formation assays showed that DATS dose-dependently inhibited the migration and angiogenesis of MDA-MB-231 cells in vitro. The expressions of L1CAM, VEGF-A, and EMT-related proteins (Slug, Snail, MMP-2) were inhibited by DATS. DATS dose-dependently inhibited HIF-1α transcriptional activity and hypoxia-induced hematogenous metastasis of MDA-MB-231 cells. It reduced the protein expression of HIF-1α, which did not involve inhibition of HIF-1α mRNA expression or ubiquitin proteasome degradation. Efficient inhibition of HIF-1α expression was required for DATS to resist breast cancer. Show less
no PDF DOI: 10.1002/mc.22686
ANGPTL4
Pei-Wen Wang, Yu-Ching Hung, Tung-Ho Wu +3 more · 2017 · Oncotarget · Impact Journals · added 2026-04-24
Hepatic fibrosis may ultimately result in organ failure and death, a reality compounded by the fact that most drugs for liver fibrosis appear to be effective only if given as a prophylactic or early t Show more
Hepatic fibrosis may ultimately result in organ failure and death, a reality compounded by the fact that most drugs for liver fibrosis appear to be effective only if given as a prophylactic or early treatment. In a dimethylnitrosamine-induced liver fibrotic model, aspartate aminotransferase/alanine aminotransferase levels could not precisely distinguish the differences between the initial stage of liver fibrosis and normal control, whereas histological examination indicated that dimethylnitrosamine treatment for two weeks has resulted in hepatic fibrogenesis. Comprehensive proteomics identified 12 proteins mainly associated with the interleukin 6-stimulated inflammatory pathway. Coordinately, cytokine profiles showed that dimethylnitrosamine administration would stimulate various signaling pathways leading to liver fibrosis. Of note, apolipoprotein A4 in serum samples obtained from patients in the early stage of liver fibrosis were significantly increased compared to the healthy controls ( Show less
📄 PDF DOI: 10.18632/oncotarget.21627
APOA4
Jianqiang Wu, Zhengguang Guo, Youhe Gao · 2017 · Cancer medicine · Wiley · added 2026-04-24
Despite advances in cancer treatments, early diagnosis of cancer is still the most promising way to improve outcomes. Without homeostatic control, urine reflects systemic changes in the body and can p Show more
Despite advances in cancer treatments, early diagnosis of cancer is still the most promising way to improve outcomes. Without homeostatic control, urine reflects systemic changes in the body and can potentially be used for early detection of cancer. In this study, a tumor-bearing rat model was established by subcutaneous injection of Walker 256 cells. Urine samples from tumor-bearing rats were collected at five time points during cancer development. Dynamic urine proteomes were profiled using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Several urine proteins that changed at multiple time points were selected as candidate cancer biomarkers and were further validated by multiple reaction monitoring (MRM) analysis. It was found that the urinary protein patterns changed significantly with cancer development in a tumor-bearing rat model. A total of 10 urinary proteins (HPT, APOA4, CO4, B2MG, A1AG, CATC, VCAM1, CALB1, CSPG4, and VTDB) changed significantly even before a tumor mass was palpable, and these early changes in urine could also be identified with differential abundance at late stages of cancer. Our results indicate that urine proteins could enable early detection of cancer at an early onset of tumor growth and monitoring of cancer progression. Show less
📄 PDF DOI: 10.1002/cam4.1225
APOA4
R-J Zheng, R-J Wu, X-D Ma · 2017 · Genetics and molecular research : GMR · added 2026-04-24
We investigated the differences between the serum proteomic spectral characteristics of acute myeloid leukemia (AML) patients and those of healthy people. We collected peripheral blood serum samples f Show more
We investigated the differences between the serum proteomic spectral characteristics of acute myeloid leukemia (AML) patients and those of healthy people. We collected peripheral blood serum samples from 62 AML patients and 15 healthy controls. After removing high-abundance proteins, low-abundance serum proteins were separated using two-dimensional gel electrophoresis to identify differences between AML patients and healthy people. We investigated the different protein dots by mass fingerprint analysis, and evaluated the results using the Masort retrieval program provided by the MSDB protein bank. To further investigate the relationship between standard chemotherapy treatment efficacy and differences in protein patterns, we divided 21 patients into two groups (A and B) according to the efficacy of standard chemotherapy. Compared with the healthy cases, the AML patients demonstrated significant abnormal expression in 14 proteins (P < 0.05); α1-trypsin inhibitor (P < 0.01), prealbumin (P < 0.01), apolipoprotein E (P < 0.010), and apolipoprotein A-IV (P < 0.01) expression decreased, whereas haptoglobin HP2 (P < 0.05), serum exogenous lectin (P < 0.05), H factor homologue protein (P < 0.05), and serum amyloid A1 (P < 0.01) expression increased. Further stratified analysis revealed that patients with high serum lectin expression had poor outcomes. The study revealed various proteins with differential expression levels in the peripheral blood of AML patients, and the difference in serum lectin expression is related to the efficiency of standard chemotherapy. Therefore, these proteins are potential diagnosis markers or prognostic indicators of AML. Show less
no PDF DOI: 10.4238/gmr16029172
APOA4
Xiao-Yan Zheng, Bi-Lian Yu, Yu-Fei Xie +2 more · 2017 · Molecular medicine reports · added 2026-04-24
It has previously been demonstrated that apolipoprotein A5 (apoA5) can be internalized by human adipocytes and significantly decreases intracellular triglyceride content. In the present study, endocyt Show more
It has previously been demonstrated that apolipoprotein A5 (apoA5) can be internalized by human adipocytes and significantly decreases intracellular triglyceride content. In the present study, endocytosis of apoA5 by adipocytes under different conditions, and the underlying mechanism by which apoA5 regulates cellular triglyceride storage, was investigated. The results revealed that the apoA5 protein was detected in human subcutaneous abdominal adipose tissues. In addition, the uptake of apoA5 was attenuated in human obese adipose tissues and in cultured adipocytes with hypertrophy or insulin resistance. Low‑density lipoprotein receptor protein 1 (LRP1) knockdown in adipocytes resulted in a decrease in internalized apoA5 content, suggesting that LRP1 serves a role in apoA5 uptake. Treatment of adipocytes with apoA5 decreased the expression of the lipid droplet‑associated proteins such as cidec and perilipin. ApoA5‑treated adipocytes demonstrated an increase in lipolysis activity and expression of uncoupling protein 1, which is the molecular effector of thermogenesis in brown adipocytes. These results suggested that decreased triglyceride accumulation in adipocytes induced by apoA5 may be associated with enhanced lipolysis and energy expenditure, which may result from reduced expression of cidec and perilipin. In conclusion, the present study demonstrated a novel role of apoA5 in regulating the intracellular triglyceride metabolism of adipocytes. The results of the present study suggested that apoA5 may serve as a potential therapeutic target for the treatment of obesity and its related disorders. Show less
📄 PDF DOI: 10.3892/mmr.2017.7461
APOA5